2011

Pearl Therapeutics’ COPD trial shows positive results

Friday, December 9, 2011

Pearl Therapeutics has reported positive top-line results from a randomized, double-blind, phase IIb, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist delivered twice a day via metered-dose inhaler in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent HFA Inhalation Aerosol, a short-acting muscarinic antagonist given four times a day. All doses of GP MDI tested produced statistically significant improvements in lung function compared to placebo. Further, doses of PT001 were identified that were non-inferior to Atrovent HFA. PT001 was well tolerated and no safety concerns were identified.

[Read More]

Janssen, Pharmacyclics collaborate to develop anti-cancer drug

Friday, December 9, 2011

Janssen Biotech, one of the Janssen Pharmaceutical companies of Johnson & Johnson, has executed an agreement with Pharmacyclics to jointly develop and market the anti-cancer compound, PCI-32765. A number of phase I and II studies with PCI-32765 are ongoing across a panel of B-cell malignancy disorders, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

[Read More]

Fang joins SRI as director of clinical manufacturing

Thursday, December 8, 2011

Jia-Hwa Fang, Ph.D., has joined SRI’s biosciences division as director of clinical manufacturing. In this new role, he will lead a team to transfer and scale-up R&D, Good Laboratory Practice (GLP), and pilot formulations for early stage clinical
trial materials in compliance with Good Manufacturing Practices (GMP). He will be responsible for developing technical, quality, and project specifications for studies in SRI’s pharmaceutical clinical manufacturing facility.

[Read More]

Molecular Partners expands research collaboration with Janssen Biotech

Thursday, December 8, 2011

Molecular Partners has entered into a strategic research collaboration and option agreement with Janssen Biotech to research, discover and develop DARPin products for the treatment of immunological diseases. The collaboration and expansion of its current agreement with the company and its affiliates aims to explore a defined set of targets, including the use of multispecific DARPins, to address diseases where continued unmet needs for effective treatment options continue to exist.

[Read More]

Adams joins Auxilium Pharmaceuticals

Thursday, December 8, 2011

Auxilium Pharmaceuticals has named Adrian Adams chief executive officer and president, effective immediately. Adams succeeds Armando Anido, who has agreed to step down as chief executive officer and president and has resigned as a member of the board of directors.

[Read More]